-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to Wind data, as of May 13, a total of 845 A-share companies have received public fund research in the second quarter, a 36% increase from the previous quart.
Among them, the pharmaceutical and biological sector is still favored by public fun.
In the second quarter, more than 100 public funds gathered to investigate this sector, reaching 10 From the perspective of individual stock companies, Junshi Bio-U, Mindray Medical, and Amic are the key pharmaceutical and biological companies investigated by the instituti.
In the second quarter, these companies received the attention of more than 100 public fun.
Among them, in the past 5 trading days (April 27 to May 6), Junshi Bio-U has obtained a total of 575 institutional surve.
According to the data, Junshi Bio is a research and development-oriented high-tech company focusing on the development of therapeutic antibodi.
In the first quarter of 2022, the company achieved an operating income of 630 million yuan, a year-on-year decrease of 602%, and a net profit loss of 396 million yuan attributable to the pare.
Some analysts believe that the increase in the company's net profit loss is mainly related to the decline in technology licensing revenue compared with the same period last ye.
However, judging from the company's 2021 annual report, in 2021, the operating income will be 025 billion yuan, a year-on-year increase of 152%; the net profit will be -720 million yuan, a sharp drop from the loss in the same period in 2020, which shows that the company is getting out of the predicament of making profi.
Regarding the reasons for the substantial increase in revenue in 2021, the company stated that it is mainly due to the substantial increase in technology licensing revenue, the increase in franchise revenue, and the sales revenue brought by the commercialization of toripalimab injection in the domestic mark.
Mindray Medical and Amic followed closely and were surveyed by more than 500 institutio.
Among them, Mindray Medical is a leading domestic medical device compa.
The company's 2021 annual report and 2022 first quarter report show that the company's annual operating income in 2021 is 2270 billion yuan, a year-on-year increase of 218%; the net profit attributable to the parent is 002 billion yuan , a year-on-year increase of 21
The performance of the first quarterly report in 2022 continued the high growth trend, achieving operating income of 943 billion yuan, a year-on-year increase of 210%; net profit attributable to the parent of 105 billion yuan, a year-on-year increase of 27
The 2021 annual report shows that Mindray Medical's life information and support business, in vitro diagnostic business, medical imaging business, and three major product lines continue to contribute to the increase in performance, driving the growth of performan.
At the same time, the company attaches great importance to R&D investme.
In 2021, R&D investment will reach 726 billion yuan, a year-on-year increase of 30
While basing itself on independent innovation, Mindray Medical has also acquired 100% equity of HyTest Invest Oy (Hai Peptide Bio), a large global supplier of in vitro diagnostic antigens and antibodies, and its subsidiaries to help Mindray Medical’s global layout of upstream and downstream industry chai.
Laying the foundation for the globalization of its in vitro diagnostics busine.
Amic belongs to the medical beauty sector compa.
In 2021, the company's revenue increased by 101% year-on-year, and the net profit attributable to the parent increased by 118% year-on-ye.
22Q1 revenue and net profit attributable to the parent increased by 61% and 64% year-on-year, respective.
It is reported that the penetration rate of the company's major single product Hi-body series has continued to increase, and the angel needle has become the second growth po.
The forward-looking layout of multiple products opens up room for future grow.
In addition, CTI has also attracted the attention of institutions, and has been investigated by a total of 448 institutio.
The company is a comprehensive third-party organization integrating testing, calibration, inspection, certification and technical services, providing one-stop solutions for global custome.
In 2021, the company's revenue will be 33 billion yuan, a year-on-year increase of 23%; the net profit attributable to the parent is 750 million yuan, a year-on-year increase of 2
In 22Q1, the revenue was 910 million yuan, a year-on-year increase of 12%; the net profit attributable to the parent was 120 million yuan, a year-on-year increase of 1
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, the pharmaceutical and biological sector is still favored by public fun.
In the second quarter, more than 100 public funds gathered to investigate this sector, reaching 10 From the perspective of individual stock companies, Junshi Bio-U, Mindray Medical, and Amic are the key pharmaceutical and biological companies investigated by the instituti.
In the second quarter, these companies received the attention of more than 100 public fun.
Among them, in the past 5 trading days (April 27 to May 6), Junshi Bio-U has obtained a total of 575 institutional surve.
According to the data, Junshi Bio is a research and development-oriented high-tech company focusing on the development of therapeutic antibodi.
In the first quarter of 2022, the company achieved an operating income of 630 million yuan, a year-on-year decrease of 602%, and a net profit loss of 396 million yuan attributable to the pare.
Some analysts believe that the increase in the company's net profit loss is mainly related to the decline in technology licensing revenue compared with the same period last ye.
However, judging from the company's 2021 annual report, in 2021, the operating income will be 025 billion yuan, a year-on-year increase of 152%; the net profit will be -720 million yuan, a sharp drop from the loss in the same period in 2020, which shows that the company is getting out of the predicament of making profi.
Regarding the reasons for the substantial increase in revenue in 2021, the company stated that it is mainly due to the substantial increase in technology licensing revenue, the increase in franchise revenue, and the sales revenue brought by the commercialization of toripalimab injection in the domestic mark.
Mindray Medical and Amic followed closely and were surveyed by more than 500 institutio.
Among them, Mindray Medical is a leading domestic medical device compa.
The company's 2021 annual report and 2022 first quarter report show that the company's annual operating income in 2021 is 2270 billion yuan, a year-on-year increase of 218%; the net profit attributable to the parent is 002 billion yuan , a year-on-year increase of 21
The performance of the first quarterly report in 2022 continued the high growth trend, achieving operating income of 943 billion yuan, a year-on-year increase of 210%; net profit attributable to the parent of 105 billion yuan, a year-on-year increase of 27
The 2021 annual report shows that Mindray Medical's life information and support business, in vitro diagnostic business, medical imaging business, and three major product lines continue to contribute to the increase in performance, driving the growth of performan.
At the same time, the company attaches great importance to R&D investme.
In 2021, R&D investment will reach 726 billion yuan, a year-on-year increase of 30
While basing itself on independent innovation, Mindray Medical has also acquired 100% equity of HyTest Invest Oy (Hai Peptide Bio), a large global supplier of in vitro diagnostic antigens and antibodies, and its subsidiaries to help Mindray Medical’s global layout of upstream and downstream industry chai.
Laying the foundation for the globalization of its in vitro diagnostics busine.
Amic belongs to the medical beauty sector compa.
In 2021, the company's revenue increased by 101% year-on-year, and the net profit attributable to the parent increased by 118% year-on-ye.
22Q1 revenue and net profit attributable to the parent increased by 61% and 64% year-on-year, respective.
It is reported that the penetration rate of the company's major single product Hi-body series has continued to increase, and the angel needle has become the second growth po.
The forward-looking layout of multiple products opens up room for future grow.
In addition, CTI has also attracted the attention of institutions, and has been investigated by a total of 448 institutio.
The company is a comprehensive third-party organization integrating testing, calibration, inspection, certification and technical services, providing one-stop solutions for global custome.
In 2021, the company's revenue will be 33 billion yuan, a year-on-year increase of 23%; the net profit attributable to the parent is 750 million yuan, a year-on-year increase of 2
In 22Q1, the revenue was 910 million yuan, a year-on-year increase of 12%; the net profit attributable to the parent was 120 million yuan, a year-on-year increase of 1
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
